# Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic Hypoglycemia

> **NCT02685852** · PHASE1 · COMPLETED · sponsor: **University of Minnesota** · enrollment: 11 (actual)

## Conditions studied

- Hyperinsulinemic Hypoglycemia

## Interventions

- **DRUG:** Exenatide
- **DRUG:** Acarbose
- **DRUG:** Exenatide Placebo
- **DRUG:** Acarbose Placebo

## Key facts

- **NCT ID:** NCT02685852
- **Lead sponsor:** University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02
- **Primary completion:** 2019-07-22
- **Final completion:** 2019-07-22
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2021-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02685852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02685852, "Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic Hypoglycemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02685852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*